Chouinard-Watkins Raphaël, Conway Valérie, Minihane Anne M, Jackson Kim G, Lovegrove Julie A, Plourde Mélanie
Research Center on Aging, Health and Social Services Centre - University Institute of Geriatrics of Sherbrooke, Sherbrooke, Canada; Departments of Physiology and.
Department of Nutrition, Norwich Medical School, University of East Anglia, Norwich, United Kingdom; and.
Am J Clin Nutr. 2015 Aug;102(2):505-13. doi: 10.3945/ajcn.114.103507. Epub 2015 Jun 17.
Carriers of the apolipoprotein E ɛ4 (APOE4) allele are lower responders to a docosahexaenoic acid (DHA) supplement than are noncarriers. This effect could be exacerbated in overweight individuals because DHA metabolism changes according to body mass index (BMI; in kg/m²).
We evaluated the plasma fatty acid (FA) response to a DHA-rich supplement in APOE4 carriers and noncarriers consuming a high-saturated fat diet (HSF diet) and, in addition, evaluated whether being overweight changed this response.
This study was part of the SATgenɛ trial. Forty-one APOE4 carriers and 41 noncarriers were prospectively recruited and consumed an HSF diet for 8-wk followed by 8 wk of consumption of an HSF diet with the addition of DHA and eicosapentaenoic acid (EPA) (HSF + DHA diet; 3.45 g DHA/d and 0.5 g EPA/d). Fasting plasma samples were collected at the end of each intervention diet. Plasma total lipids (TLs) were separated into free FAs, neutral lipids (NLs), and phospholipids by using solid-phase extraction, and FA profiles in each lipid class were quantified by using gas chromatography.
Because the plasma FA response to the HSF + DHA diet was correlated with BMI in APOE4 carriers but not in noncarriers, the following 2 groups were formed according to the BMI median: low BMI (<25.5) and high BMI (≥25.5). In response to the HSF + DHA diet, there were significant BMI × genotype interactions for changes in plasma concentrations of arachidonic acid and DHA in phospholipids and TLs and of EPA in NLs and TLs (P ≤ 0.05). APOE4 carriers were lower plasma responders to the DHA supplement than were noncarriers but only in the high-BMI group.
Our findings indicate that apolipoprotein E genotype and BMI may be important variables that determine the plasma long-chain PUFA response to dietary fat manipulation. APOE4 carriers with BMI ≥25.5 may need higher intakes of DHA for cardiovascular or other health benefits than do noncarriers.
与非载脂蛋白E ε4(APOE4)等位基因携带者相比,APOE4等位基因携带者对二十二碳六烯酸(DHA)补充剂的反应较低。超重个体的这种效应可能会加剧,因为DHA代谢会根据体重指数(BMI;单位为kg/m²)发生变化。
我们评估了APOE4携带者和非携带者在食用高饱和脂肪饮食(HSF饮食)时,血浆脂肪酸(FA)对富含DHA的补充剂的反应,此外,还评估了超重是否会改变这种反应。
本研究是SATgenɛ试验的一部分。前瞻性招募了41名APOE4携带者和41名非携带者,他们食用HSF饮食8周,随后食用添加了DHA和二十碳五烯酸(EPA)的HSF饮食8周(HSF + DHA饮食;3.45 g DHA/天和0.5 g EPA/天)。在每种干预饮食结束时采集空腹血浆样本。通过固相萃取将血浆总脂质(TLs)分离为游离脂肪酸、中性脂质(NLs)和磷脂,并使用气相色谱法对每种脂质类别的FA谱进行定量。
由于APOE4携带者对HSF + DHA饮食的血浆FA反应与BMI相关,而非携带者则不然,因此根据BMI中位数形成了以下两组:低BMI(<25.5)和高BMI(≥25.5)。对于HSF + DHA饮食,磷脂和TLs中花生四烯酸和DHA以及NLs和TLs中EPA的血浆浓度变化存在显著的BMI×基因型相互作用(P≤0.05)。APOE4携带者对DHA补充剂的血浆反应低于非携带者,但仅在高BMI组中如此。
我们的研究结果表明,载脂蛋白E基因型和BMI可能是决定血浆长链多不饱和脂肪酸对饮食脂肪操纵反应的重要变量。BMI≥25.5的APOE4携带者可能比非携带者需要更高剂量的DHA以获得心血管或其他健康益处。